Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curatis Holding AGXSWX:CURN -1.72%30 EV-to-EBIT is -78.40 as of Jul. 20, 2026. GuruFocus rates XSWX:CURN with a GF Score™ of 30/100. The stock has 7 warning signs investors should review. Among 689 Drug Manufacturers companies, Curatis Holding AG ranks worse than 145137.74% on this metric.
Curatis Holding AG (XSWX:CURN) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Curatis Holding AG's Enterprise Value for the quarter that ended in Dec. 2025 was CHF59.98 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Curatis Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-1.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curatis Holding AG EV-to-EBIT Related Terms
Curatis Holding AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Curatis Holding AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:CURN vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curatis Holding AG EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Curatis Holding AG's EV-to-EBIT falls into.
Curatis Holding AG's current Enterprise Value is CHF118.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Curatis Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-1.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curatis Holding AG (XSWX:CURN) has a EV-to-EBIT of -78.40 as of Jul. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Curatis Holding AG and its competitors. According to the industry distribution chart, Curatis Holding AG ranks #999999 out of 689 companies in the Drug Manufacturers industry.
Is Curatis Holding AG's EV-to-EBIT too high?
Curatis Holding AG's current EV-to-EBIT is -78.40. Based on the distribution chart, Curatis Holding AG ranks #999999 out of 689 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Curatis Holding AG has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curatis Holding AG ranks #999999 out of 689 companies for EV-to-EBIT. This places Curatis Holding AG in the lower half of its industry. The industry median EV-to-EBIT is 16.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.00, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Curatis Holding AG and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curatis Holding AG's current EV-to-EBIT is -78.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current EV-to-EBIT of -78.40. The current EV-to-EBIT is -78.40. Curatis Holding AG's overall GF Score™ is 30/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current EV-to-EBIT is -78.40 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
30GF Score
Get the complete analysis for XSWX:CURN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CURN has been successfully added to your 
